Lynx MD, an artificial intelligence (AI)-based healthcare platform for clinical and operational data collaboration, has raised $12 million in seed financing, the company announced Monday. The oversubscribed round was led by MizMaa Ventures with participation from New York Life Ventures, Amdocs, and iAngels, as well as existing investors Triventures, UpWest and notable angels.
Follow Israel Hayom on Facebook and Twitter
Lynx's platform performs de-identification on all types of data including imaging, genomics, doctors' notes, device data, medical records, labs, and more. The platform includes a full AI development workbench and can be deployed in just days with little to no customer IT resources required, the company says.
"AI and machine learning models are only as good as the data which feeds them. Quality, variety and volume of the data are key," said Omer Dror, co-founder and CEO of Lynx.
"This is especially true and important in the healthcare industry where people's lives are at stake. AI has incredible potential to help researchers, drug developers, and doctors discover new ways to improve patient outcomes and the healthcare industry overall, but only if we solve the data access conundrum," Dror added.
Lynx will use the new capital for commercial acceleration, and expansion of its customer success, sales, and marketing teams in the US and R&D team in Israel.
